S J B Vos

Summary

Publications

  1. pmc NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers
    Stephanie J B Vos
    Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands Electronic address
    Neurobiol Aging 44:1-8. 2016
  2. pmc Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage
    Stephanie J B Vos
    1 Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht, The Netherlands
    Brain 138:1327-38. 2015
  3. pmc Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
    Stephanie Jb Vos
    Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht, Netherlands Electronic address
    Lancet Neurol 12:957-65. 2013
  4. doi request reprint Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI
    Stephanie J B Vos
    Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht, The Netherlands
    Neurology 80:1124-32. 2013
  5. doi request reprint Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI
    Stephanie Vos
    Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht, The Netherlands
    Neurobiol Aging 33:2272-81. 2012
  6. ncbi request reprint [The role of CSF markers in the early diagnosis of Alzheimer's disease]
    S J B Vos
    Afdeling Psychiatrie en Neurophyschologie, MUMC, Maastricht
    Tijdschr Psychiatr 53:647-53. 2011

Detail Information

Publications6

  1. pmc NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers
    Stephanie J B Vos
    Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands Electronic address
    Neurobiol Aging 44:1-8. 2016
    ..This highlights the heterogeneity of the definition of neuronal injury and has important implications for clinical trials using biomarkers for enrollment or as surrogate end point measures. ..
  2. pmc Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage
    Stephanie J B Vos
    1 Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht, The Netherlands
    Brain 138:1327-38. 2015
    ..For clinical trials, selection of subjects in the National Institute of Ageing-Alzheimer Association high Alzheimer's disease likelihood group or the International Working Group-2 prodromal Alzheimer's disease group could be considered. ..
  3. pmc Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
    Stephanie Jb Vos
    Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht, Netherlands Electronic address
    Lancet Neurol 12:957-65. 2013
    ..We aimed to investigate the prevalence and long-term outcome of preclinical Alzheimer's disease according to these criteria...
  4. doi request reprint Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI
    Stephanie J B Vos
    Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht, The Netherlands
    Neurology 80:1124-32. 2013
    ....
  5. doi request reprint Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI
    Stephanie Vos
    Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht, The Netherlands
    Neurobiol Aging 33:2272-81. 2012
    ..These results provide further support for the use of CSF and magnetic resonance imaging biomarkers to identify prodromal AD...
  6. ncbi request reprint [The role of CSF markers in the early diagnosis of Alzheimer's disease]
    S J B Vos
    Afdeling Psychiatrie en Neurophyschologie, MUMC, Maastricht
    Tijdschr Psychiatr 53:647-53. 2011
    ..Biomarkers in cerebrospinal fluid (CSF) are being used increasingly to diagnose early Alzheimer's disease (AD). A CSF profile that is suggestive of ad is an abnormal ratio of the proteins Ab1-42 to total tau...